Denali Therapeutics
A biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases.
The USA- based company is pursuing new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB, and guiding development through biomarkers that demonstrate target and pathway engagement.
Latest Denali Therapeutics News & Features
28 June 2024
25 June 2024
24 June 2024
19 June 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze